A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1 or Genotype 4 HCV Infection
Phase of Trial: Phase III
Latest Information Update: 21 Jun 2019
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Janssen-Cilag
- 24 Sep 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 16 Mar 2015 Results published in Results published in Medivir AB media release.
- 12 Jan 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.